The monoclonal CD4 antibody M-T413 inhibits cellular infection with human immunodeficiency virus after viral attachment to the cell membrane: an approach to postexposure prophylaxis.
Infectious cellular uptake of human immunodeficiency virus (HIV) is initiated by a complex sequence of interactions between the viral envelope gp120/gp41 complex and the cellular CD4 receptor resulting in the exposure of a hydrophobic region of gp41 that mediates the irreversible fusion of the virus with the cell membrane. Here we show that viral penetration into a susceptible cell can be inhibited by the high-affinity monoclonal CD4 antibody (CD4 mAb) M-T413 even when it is added as late as 30-120 min after the initial contact of virus with the cell membrane. Inhibition of infection was assessed by monitoring cultures for 34 days after exposure to virus using four different methods simultaneously, including detection of viral DNA by PCR. The interval during which HIV remains sensitive to postbinding neutralization by CD4 mAb depends on strain of virus and type of target cell. Preparations of recombinant soluble CD4 (and the immunoadhesin CD4-IgG1) were much less efficient when compared with mAb M-T413, particularly in blocking infection by fresh HIV-1 isolates. Also cellular transmission of HIV, as determined by syncytia formation within 24 hr, was prevented by mAb M-T413 when added within 45 min of contact of infected H9 cells with uninfected C8166 cells. Together with the favorable clinical experience obtained with CD4 mAbs as immunomodulatory drugs, these data suggest that infusion of CD4 mAb M-T413 may be a therapeutic modus for immediate prophylactic intervention after occupational exposure to HIV and for prevention of intrapartum mother-to-infant HIV transmission.
Rieber
E P
EP
Institute for Immunology, University of Munich, Federal Republic of Germany.
Federle
C
C
Reiter
C
C
Krauss
S
S
Gürtler
L
L
Eberle
J
J
Deinhardt
F
F
Riethmüller
G
G
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D000936:Antigen-Antibody Complex; D015704:CD4 Antigens / Q000235:genetics / Q000276:immunology*; D016466:CHO Cells; D002460:Cell Line; D002462:Cell Membrane / Q000276:immunology / Q000382:microbiology; D002478:Cells, Cultured; D006224:Cricetinae; D015726:Giant Cells / Q000276:immunology; D006678:HIV / Q000276:immunology / Q000502:physiology*; D015699:HIV Envelope Protein gp120 / Q000276:immunology; D015497:HIV-1 / Q000276:immunology / Q000502:physiology; D015498:HIV-2 / Q000276:immunology / Q000502:physiology; D006801:Humans; D007074:Immunoglobulin G / Q000235:genetics / Q000276:immunology; D007700:Kinetics; D011994:Recombinant Proteins / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology* / Q000382:microbiology
D000911:Antibodies, Monoclonal; D000936:Antigen-Antibody Complex; D015704:CD4 Antigens; D015699:HIV Envelope Protein gp120; D007074:Immunoglobulin G; D011994:Recombinant Proteins